Loading the security overview…
Where the tokens are
Standardised from the company’s filings, newest period first, labelled with the company’s own fiscal calendar. A line the company does not report is left off rather than shown as zero; margins and free cash flow are worked out here, and only where every input is present.
| Line item | Q2 FY262026-06-30 | Q1 FY262026-03-31 | Q4 FY252025-12-31 | Q3 FY252025-09-30 | Q2 FY252025-06-30 | Q1 FY252025-03-31 | Q4 FY242024-12-31 | Q3 FY242024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $783.30M | $781.50M | $790.20M | $799.50M | $798.60M | $794.40M | $735.90M | $748.90M |
| Cost of revenue | $99.50M | $133.40M | $103.40M | $100.90M | $87.60M | $92.50M | $75.90M | $83.10M |
| Gross profit | $683.80M | $648.10M | $686.80M | $698.60M | $711.00M | $701.90M | $660.00M | $665.80M |
| Gross margin | 87.3% | 82.9% | 86.9% | 87.4% | 89.0% | 88.4% | 89.7% | 88.9% |
| Research and development | $146.30M | $138.20M | $139.50M | $127.50M | $134.00M | $149.00M | $133.80M | $103.50M |
| Selling, general and administrative | $206.70M | $184.10M | $190.60M | $182.60M | $212.50M | $170.10M | $168.50M | $219.20M |
| Operating expenses | $353.00M | $322.30M | $330.10M | $310.10M | $346.50M | $319.10M | $302.30M | $322.70M |
| Operating income | $330.80M | $325.80M | $356.70M | $388.50M | $364.50M | $382.80M | $357.70M | $343.10M |
| Operating margin | 42.2% | 41.7% | 45.1% | 48.6% | 45.6% | 48.2% | 48.6% | 45.8% |
| EBITDA | $355.00M | $348.40M | $379.50M | $410.40M | $385.60M | $402.60M | $377.40M | $362.20M |
| Interest income | $31.50M | $41.80M | $43.20M | $46.40M | $51.30M | $51.10M | $49.30M | $49.80M |
| Interest expense | −$2.90M | −$3.00M | −$3.10M | −$3.00M | −$7.30M | −$6.10M | −$7.90M | −$10.10M |
| Income before taxes | $372.70M | $318.30M | $444.00M | $438.00M | $408.40M | $423.50M | $396.50M | $388.60M |
| Income taxes | $39.70M | $43.40M | $79.70M | $99.30M | $98.90M | $101.30M | $95.20M | $79.50M |
| Net income | $333.00M | $274.90M | $364.30M | $338.70M | $309.50M | $322.20M | $301.30M | $309.10M |
| Net margin | 42.5% | 35.2% | 46.1% | 42.4% | 38.8% | 40.6% | 40.9% | 41.3% |
| EPS, basic | $7.82 | $6.32 | $8.39 | $7.73 | $6.86 | $7.18 | $6.73 | $6.93 |
| EPS, diluted | $7.27 | $5.82 | $7.69 | $7.16 | $6.41 | $6.63 | $6.23 | $6.39 |
| Diluted shares | 45.80M | 47.20M | 47.40M | 47.30M | 48.30M | 48.60M | 48.40M | 48.40M |
Figures describe United Therapeutics shares, not any token. As of Aug 5, 2026, from Massive's standardised financials. The company reports these figures; a token's issuer holds the shares and reports nothing of its own here.